Samsung Bioepis reveals clinical trial results of SB3 at ASCO in U.S.
Samsung Bioepis(CEO/President Han-Seung Ko) revealed the 1-year clinical trial result of SB3(Herceptin biosimilar, generic name: trastuzumab, European name: Ontruzant, Korean name: Samfenet), a breast cancer therapy.
The recently announced clinical trial result is the first 1-year tracking resul...
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.